Drug Trial News

RSS

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

ActiveSite Pharmaceuticals, Inc., announced today the online publication of a study in the journal Diabetes that describes the effectiveness of its novel plasma kallikrein inhibitor ASP-440 in reducing blood-retinal barrier breakdown in a rodent model of diabetes.

28 Mar 2011

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started for the Phase 1 clinical trial testing the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes (study # MF101-008), also known as "menopausal hot flashes."

28 Mar 2011

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

28 Mar 2011

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.

28 Mar 2011

Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point

Researchers studying a new medication for neuropathic pain have reported intriguing findings about placebo response versus drug response from a Phase 2a proof-of-concept study. They presented their findings in a poster session at the 2011 International Conference on Accelerating the Development of Enhanced Pain Treatments.

28 Mar 2011

Cancer drug Gleevec may hold promise against scleroderma: Study

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

28 Mar 2011

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

AVEO Pharmaceuticals, Inc. today announced that preclinical data on tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company's monoclonal antibody pipeline will be presented during poster sessions at the American Association for Cancer Research 102nd Annual Meeting 2011 being held April 2-6, 2011 in Orlando, Fla.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

XTL announces MinoGuard acquisition

XTL announced on March 24, 2011, it entered into a term sheet to acquire the activity of MinoGuard Ltd. by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

25 Mar 2011

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.

25 Mar 2011

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2010 and provided a review of the Company's operational and financial progress for 2010 and to the current date.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries

Little is known about the impact of early aggressive regional analgesia on short- and long-term pain and psychological outcomes of soldiers with major combat injuries.

25 Mar 2011

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

SARcode Corporation announced today that clinical data for their lead compound, SAR 1118, has been accepted for presentation during the upcoming Association for Research in Vision and Ophthalmology Annual Meeting being held May 1–May 5, 2011, in Fort Lauderdale, Florida.

25 Mar 2011

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego.

25 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011

Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today positive top-line results of a Phase 1 study of PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole.

25 Mar 2011

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Oncolytics Biotech Inc. today announced that it has completed patient enrollment in its U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers.

25 Mar 2011

Drug Trial News

ActiveSite's ASP-440 plasma kallikrein inhibitor effective in reducing diabetes-induced blood-retinal barrier breakdown

Bionovo initiates enrollment in Menerba Phase 1 clinical trial for menopausal hot flushes

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Phase 2a study of DARA BioSciences KRN5500 in treatment of cancer pain reaches primary end-point

Cancer drug Gleevec may hold promise against scleroderma: Study

AVEO to present tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Genentech's Lucentis Phase III trials in DME meets primary endpoints

XTL announces MinoGuard acquisition

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Isotechnika fourth quarter consolidated net loss increases to $2.42 million

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Study examines regional analgesia effect on long-term outcomes in soldiers with combat injuries

SARcode's SAR 1118 Phase 2 data against dry eye to be presented at ARVO meeting

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Positive top-line results from POZEN's PA32540 Phase 1 study against cardiovascular disease

Oncolytics completes patient enrollment in REOLYSIN Phase 2 trial against head, neck cancers

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News